# Chemical Name Cas No API Indication
1 5-bromo-1-(2-fluoro-6-(trifluoromethyl)benzyl)-6-methylpyrimidine-2,4(1H,3H)-dione 830346-48-0 Elagolix intermediate Antineoplastic
2 1-((4′-chloro-5,5-dimethyl-3,4,5,6-tetrahydro-[1,1′-biphenyl]-2-yl)methyl)piperazine 2HCl 1628047-87-9 Venetoclax Intermediate Multiple use
3 N-(3-chloro-4-fluorophenyl)-7-fluoro-6-nitroquinazolin-4-amine 162012-67-1 Afatinib Intermediate Oncology
4 Tetraheptylammonium bromide 4368-51-8 Quaternary ammonium salts Multiple use
5 Tetra Decyl ammonium bromide 14937-42-9 Quaternary ammonium salts Multiple use
6 2-Amino thiophenol 137-07-5 CisLactam Antihypertensive
7 9-benzyl-9-azabicyclo[3.3.1]nonan-3-one 2291-58-9 Speciality chemicals Not applicable
8 1-(4-fluorophenyl)-N-ethylpropan-2-amine HCl 3823-31-2 Speciality chemicals Not applicable
9 2,2-diphenylcyclopropane-1-carbonitrile 30932-41-3 Cibenzoline intermediate Antiarrhythmic
10 5-Hydroxy-3,4-dihydrocarbostyril 30389-33-4 Carteolol.HCl intermediate Cardiovascular Agents
11 3,4-Dichlorobenzonitrile 6574-99-8 Speciality chemicals Multiple use
12 Hexane-1,6-diamine 124-09-4 Speciality chemicals Multiple use
13 4-(Dimethylamino)butyraldehyde Diethyl Acetal 1116-77-4 Sumatriptan Intermediate Antimigraine
14 5-Methylisoxazole-4-carboxylic acid 42831-50-5 Teriflunomide intermediate CNS
15 2-[(5-bromo-2-methylphenyl)methyl]-5-(4-fluorophenyl)thiophene 1030825-20-7 Canagliflozin Intermediate Antidiabetic
16 2, 3, 4, 6-Tetrakis-O-trimethylsilyl-D-glucono-1,5-lactone 32384-65-9 Canagliflozin, Dapagliflozin,Empagliflozin, Ipragliflozin Antidiabetic
17 1-(4-chloro Benzhydryl) Piperazine 303-26-4 Cetirizine.2HCl Intermediate Antihistamines
18 N-[4-(4-Fluorophenyl)-5-formyl-6-(1-methylethyl)-2-pyrimidinyl]-N-methyl-methanesulfonamide (Z-8) 147118-37-4 Rosuvastatin Intermediates Cardiovascular disease
19 4-(4-Fluorophenyl)-6-isopropyl-2-[(N-methyl-n-methylsulfonyl)amino]pyrimidine-5-yl-methanol (Z-7) 147118-36-3 Rosuvastatin Intermediates Cardiovascular disease
20 Methyl Isobutyrylacetate (MIBA) 42558-54-3 Rosuvastatin Intermediates Cardiovascular disease
21 Furan-2-yl(piperazin-1-yl)methanone 40172-95-0 Prazosin.HCl Cardiovascular disease
22 2-chloro-6,7-dimethoxyquinazolin-4-amine 23680-84-4 Alfuzosin Benign prostatic hyperplasia
23 (S,S)-2,8-Diazabicyclo[4,3,0]nonane 151213-40-0 Moxifloxacin Quinolone antibiotics
24 1-phenyl-2-(1-pyrrolidinyl)-1-hexanone HCl 13415-59-3 Speciality chemicals Multiple use
25 5,6-Dimethoxy-1-indanone 2107-69-9 Donepezil Alzheimers’s Disease
26 Pyridine-4-Carboxaldehyde 872-85-5 Donepezil Alzheimers’s Disease
27 2-Chloro-4-amino-6,7-dimethoxyquinazoline 23680-84-4 Doxazosin Alpha Blocker
28 N-(1 4-Benzodioxan-2-carbonyl)-Piperazine 70918-00-2 Doxazosin Alpha Blocker
29 1,2,3,9-Tetrahydro-9-methyl-4(H)-Carbazole 27387-31-1 Ondansetron Serotonin Blocker
30 N-Methyl-4-diazanylsulfabenzamide 88933-16-8 Sumatriptan Anti Migraine
31 4-Amino-2-methyl-10H-thiene[2,3-b][1,5]benzodiazepine hydrochloride 138564-60-0 Olanzapine Anti Migraine

Electro Active Polymers

# Chemical Name Cas No Type Category
1 3,4-Ethylenedioxythiophene (EDOT) 126213-50-1 Electro Active Monomer Performance/ Specialty Chemical
2 2-butyl-2,3-dihydrothieno[3,4-b]-1,4-dioxin (Butyl-EDOT) 552857-06-4 Electro Active Monomer Performance/ Specialty Chemical
# Chemical Name Cas No Therapeutic Category Dossier Availability DMF Availability (US,EU,JP.)
1 Levocetirizine 2HCl 130018-87-0 Antihistamine FY2018 FY2019
2 Cetirizine 2HCl 83881-52-1 Antihistamine FY2018 FY2019
3 Rosuvastatin calcium 147098-20-2 Antihyperlipidemic FY2019 FY2020
4 Dronedarone. HCl 141625-93-6 Antiarrhythmic FY2019 FY2020
5 Lacosamide 175481-36-4 Anticonvulsant FY2019 FY2020
6 Mirabegron 223673-61-8 Urinary antispasmodics FY2019 FY2020
7 Sitagliptin 486459-71-6 Antidiabetic FY2019 FY2020
8 Rivaroxaban 366789-02-8 Anticoagulant FY2019 FY2020
9 Ticagrelor 274693-27-5 Thromboembolic disorders FY2019 FY2020
10 Dapagliflozin 461432-26-8 Antidiabetic FY2019 FY2020
11 Macitentan 441798-33-0 Pulmonary hypertension FY2019 FY2020
12 Linagliptin 668270-12-0 Antidiabetic FY2019 FY2020
13 Vildagliptin 274901-16-5 Antidiabetic FY2019 FY2020
14 Canagliflozin 842133-18-0 Antidiabetic FY2019 FY2020
15 Macitentan 441798-33-0 Pulmonary hypertension FY2019 FY2020
16 Trazodone HCl 25332-39-2 Antidepressant FY2019 FY2019

Manufacturing facility

LAXAI has a 2 world-class API manufacturing facilities in the city of Hyderabad, capable of handling new, complex and hazardous reactions. Unit-I is expansive, spread over an area of 12 acres with WHO-GMP certification catering to less regulated markets. Unit-II caters to regulated markets with regulatory approvals from international regulatory authorities like USFDA,EDQM, PMDA,KFDA, COFEPRIS,UK-MHRA. LAXAI supplies APIs, NCEs, cGMP intermediates and KSMs to global innovators. It is equipped with flexible, versatile and advanced infrastructures.

Key features of the facilities:

These features ensure an effective structural methodology at workplace which includes manufacturing of quality products, rational and effective use of available resources, minimization of waste along with good safety and hygiene standards. Safety aspects have been given utmost importance, in all aspects including plant installation, equipment, systems and trained personnel to ensure smooth productivity. Combination of a dedicated team and world class production techniques guarantee delivery of products to customers across the globe.

Clean room facility: